107 related articles for article (PubMed ID: 19391415)
21. [Focus on multi-morbidity patients. Considering the greatest measure of therapy safety].
MMW Fortschr Med; 2007 Dec; 149(49-50):59. PubMed ID: 18236986
[No Abstract] [Full Text] [Related]
22. All PPIs equivalent for treatment of GERD.
J Fam Pract; 2005 Dec; 54(12):1024. PubMed ID: 16370078
[No Abstract] [Full Text] [Related]
23. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Miner P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
[TBL] [Abstract][Full Text] [Related]
24. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitors.
Grover JK; Vats V
Trop Gastroenterol; 1999; 20(1):16-28. PubMed ID: 10464444
[No Abstract] [Full Text] [Related]
26. [Taking metabolic pathways into consideration. Approved drug against problematic interactions ].
MMW Fortschr Med; 2009 Jan; 151(5):47. PubMed ID: 19391416
[No Abstract] [Full Text] [Related]
27. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
Devault KR
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
[TBL] [Abstract][Full Text] [Related]
28. [Proton pump inhibition: more than only reflux therapy].
MMW Fortschr Med; 2008 Nov; 150(46):48-9. PubMed ID: 19133361
[No Abstract] [Full Text] [Related]
29. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
30. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
31. [Graded therapy in reflux disease. "In severe cases 40 mg., in milder 20 mg."].
Gillessen A
MMW Fortschr Med; 2004 Mar; 146(11):54. PubMed ID: 15152771
[No Abstract] [Full Text] [Related]
32. Pantoprazole available without a prescription: new status. Better than H2 receptor agonists, but not for pregnant women.
Prescrire Int; 2009 Dec; 18(104):250. PubMed ID: 20025090
[TBL] [Abstract][Full Text] [Related]
33. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
34. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
Kim JD
J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268
[No Abstract] [Full Text] [Related]
35. [Reflux therapy in the elderly].
Krankenpfl J; 2005; 43(7-10):182. PubMed ID: 16515255
[No Abstract] [Full Text] [Related]
36. Lansoprazole overutilization: methods for step-down therapy.
Pohland CJ; Scavnicky SA; Lasky SS; Good CB
Am J Manag Care; 2003 May; 9(5):353-8. PubMed ID: 12744297
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
38. [Stubborn reflux pain, inconspicuous esophagus. Which therapy brings the fastest relief?].
MMW Fortschr Med; 2004 Mar; 146(11):54. PubMed ID: 15152770
[No Abstract] [Full Text] [Related]
39. [The influence of gastroesophageal reflux on the course and therapy of bronchial asthma].
Samoliński B
Pol Merkur Lekarski; 2006 Oct; 21(124):307-9. PubMed ID: 17205765
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Goh KL; Benamouzig R; Sander P; Schwan T;
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
